Dual IFN-γ/hypoxia priming enhances immunosuppression of mesenchymal stromal cells through regulatory proteins and metabolic mechanisms

• Published in: Journal of immunology and regenerative medicine Vol. 1; pp. 45 - 56
• Main Authors: Wobma, Holly M, Kanai, Mariko, Ma, Stephen P, Shih, Ying, Li, Hao Wei, Duran-Struuck, Raimon, Winchester, Robert, Goeta, Shahar, Brown, Lewis M, Vunjak-Novakovic, Gordana
• Format: Journal Article
• Language: English
• Published: Netherlands 01.03.2018
• Subjects: Mesenchymal stromal cells; hypoxia; priming; immunosuppression; metabolism; interferon gamma
• DOI: 10.1016/j.regen.2018.01.001
• ISSN: 2468-4988

The immunosuppressive capacity of human mesenchymal stromal cells (MSCs) renders them promising candidates for treating diverse immune disorders. However, after hundreds of clinical trials, there are still no MSC therapies approved in the United States. MSCs require specific cues to adopt their immunosuppressive phenotype, and yet most clinical trials use cells expanded in basic culture medium and growth conditions. We propose that priming MSCs prior to administration will improve their therapeutic efficacy. Interferon-gamma (IFN-γ) priming are cues common to situations of immune escape that have individually shown promise as MSC priming cues but have not been systematically compared. Using mixed lymphocyte reactions, we show that priming MSCs with either cue alone improves T-cell inhibition. However, combining the two cues results in additive effects and markedly enhances the immunosuppressive phenotype of MSCs. We demonstrate that IFN-γ induces expression of numerous immunosuppressive proteins (IDO, PD-L1, HLA-E, HLA-G), whereas hypoxia switches MSCs to glycolysis, causing rapid glucose consumption and production of T-cell inhibitory lactate levels. Dual IFN-γ/hypoxia primed MSCs display both attributes and have even higher induction of immunosuppressive proteins over IFN-γ priming alone (IDO and HLA-G), which may reflect another benefit of metabolic reconfiguration.